SE9903534L - Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning - Google Patents

Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning

Info

Publication number
SE9903534L
SE9903534L SE9903534A SE9903534A SE9903534L SE 9903534 L SE9903534 L SE 9903534L SE 9903534 A SE9903534 A SE 9903534A SE 9903534 A SE9903534 A SE 9903534A SE 9903534 L SE9903534 L SE 9903534L
Authority
SE
Sweden
Prior art keywords
carrier
human papillomavirus
capsid protein
oligo
major capsid
Prior art date
Application number
SE9903534A
Other languages
English (en)
Other versions
SE9903534D0 (sv
SE514982C2 (sv
Inventor
Per Antonsson
Karin Kristensson
Marie Wallen-Oehman
Joakim Dillner
Peter Lando
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE9903534A priority Critical patent/SE514982C2/sv
Publication of SE9903534D0 publication Critical patent/SE9903534D0/sv
Priority to EEP200200157A priority patent/EE200200157A/xx
Priority to NZ516725A priority patent/NZ516725A/xx
Priority to YU22202A priority patent/YU22202A/sh
Priority to JP2001526572A priority patent/JP2003510064A/ja
Priority to CZ20021023A priority patent/CZ20021023A3/cs
Priority to EP00966633A priority patent/EP1222200B1/en
Priority to SK422-2002A priority patent/SK4222002A3/sk
Priority to MXPA02003328A priority patent/MXPA02003328A/es
Priority to KR1020027004124A priority patent/KR20020047195A/ko
Priority to CA002384723A priority patent/CA2384723A1/en
Priority to BR0014666-8A priority patent/BR0014666A/pt
Priority to AT00966633T priority patent/ATE313559T1/de
Priority to PCT/SE2000/001808 priority patent/WO2001023422A1/en
Priority to RU2002111554/13A priority patent/RU2002111554A/ru
Priority to PL00355012A priority patent/PL355012A1/xx
Priority to DE60025016T priority patent/DE60025016D1/de
Priority to IL14874100A priority patent/IL148741A0/xx
Priority to TR2002/00802T priority patent/TR200200802T2/xx
Priority to AU76951/00A priority patent/AU771481B2/en
Priority to HU0202770A priority patent/HUP0202770A3/hu
Priority to CN00812618A priority patent/CN1373771A/zh
Publication of SE9903534L publication Critical patent/SE9903534L/sv
Publication of SE514982C2 publication Critical patent/SE514982C2/sv
Priority to HR20020092A priority patent/HRP20020092A2/hr
Priority to ZA200200886A priority patent/ZA200200886B/en
Priority to NO20020615A priority patent/NO20020615L/no
Priority to US10/759,125 priority patent/US20040146531A1/en
Priority to AU2004201964A priority patent/AU2004201964A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
SE9903534A 1999-01-15 1999-09-30 Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning SE514982C2 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE9903534A SE514982C2 (sv) 1999-09-30 1999-09-30 Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
CN00812618A CN1373771A (zh) 1999-09-30 2000-09-19 疫苗
AT00966633T ATE313559T1 (de) 1999-09-30 2000-09-19 Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen
RU2002111554/13A RU2002111554A (ru) 1999-09-30 2000-09-19 Вакцина
YU22202A YU22202A (sh) 1999-09-30 2000-09-19 Vakcina
JP2001526572A JP2003510064A (ja) 1999-09-30 2000-09-19 ワクチン
CZ20021023A CZ20021023A3 (cs) 1999-09-30 2000-09-19 Vakcína
EP00966633A EP1222200B1 (en) 1999-09-30 2000-09-19 Fusion protein between HPV-L1 and a peptide, capable of forming a VLP and that functions as a vehicle for introduction of a peptide in a cell and medical uses thereof
SK422-2002A SK4222002A3 (en) 1999-09-30 2000-09-19 Vaccine
MXPA02003328A MXPA02003328A (es) 1999-09-30 2000-09-19 Vacuna.
KR1020027004124A KR20020047195A (ko) 1999-09-30 2000-09-19 백신
CA002384723A CA2384723A1 (en) 1999-09-30 2000-09-19 Vaccine
BR0014666-8A BR0014666A (pt) 1999-09-30 2000-09-19 Vacina
EEP200200157A EE200200157A (et) 1999-09-30 2000-09-19 Vaktsiin
PCT/SE2000/001808 WO2001023422A1 (en) 1999-09-30 2000-09-19 Vaccine
NZ516725A NZ516725A (en) 1999-09-30 2000-09-19 Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
PL00355012A PL355012A1 (en) 1999-09-30 2000-09-19 Vaccine
DE60025016T DE60025016D1 (de) 1999-09-30 2000-09-19 Fusionsprotein aus HPV-L1 und einem Peptid, das ein VLP bilden kann und als Vehikel zum EInschleusen eines Peptids in eine Zelle dienen kann, sowie dessen medizinische Verwendungen
IL14874100A IL148741A0 (en) 1999-09-30 2000-09-19 Vaccine
TR2002/00802T TR200200802T2 (tr) 1999-09-30 2000-09-19 Aşı
AU76951/00A AU771481B2 (en) 1999-09-30 2000-09-19 Vaccine
HU0202770A HUP0202770A3 (en) 1999-09-30 2000-09-19 Human papilloma virus vaccine
HR20020092A HRP20020092A2 (en) 1999-09-30 2002-01-29 Vaccine
ZA200200886A ZA200200886B (en) 1999-09-30 2002-01-31 Vaccine.
NO20020615A NO20020615L (no) 1999-09-30 2002-02-08 Vaksine
US10/759,125 US20040146531A1 (en) 1999-09-30 2004-01-20 Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
AU2004201964A AU2004201964A1 (en) 1999-01-15 2004-05-10 Bandwidth transfer switching system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903534A SE514982C2 (sv) 1999-09-30 1999-09-30 Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning

Publications (3)

Publication Number Publication Date
SE9903534D0 SE9903534D0 (sv) 1999-09-30
SE9903534L true SE9903534L (sv) 2001-03-31
SE514982C2 SE514982C2 (sv) 2001-05-28

Family

ID=20417209

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903534A SE514982C2 (sv) 1999-01-15 1999-09-30 Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning

Country Status (25)

Country Link
EP (1) EP1222200B1 (sv)
JP (1) JP2003510064A (sv)
KR (1) KR20020047195A (sv)
CN (1) CN1373771A (sv)
AT (1) ATE313559T1 (sv)
AU (1) AU771481B2 (sv)
BR (1) BR0014666A (sv)
CA (1) CA2384723A1 (sv)
CZ (1) CZ20021023A3 (sv)
DE (1) DE60025016D1 (sv)
EE (1) EE200200157A (sv)
HR (1) HRP20020092A2 (sv)
HU (1) HUP0202770A3 (sv)
IL (1) IL148741A0 (sv)
MX (1) MXPA02003328A (sv)
NO (1) NO20020615L (sv)
NZ (1) NZ516725A (sv)
PL (1) PL355012A1 (sv)
RU (1) RU2002111554A (sv)
SE (1) SE514982C2 (sv)
SK (1) SK4222002A3 (sv)
TR (1) TR200200802T2 (sv)
WO (1) WO2001023422A1 (sv)
YU (1) YU22202A (sv)
ZA (1) ZA200200886B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
PL1730175T3 (pl) * 2004-03-24 2010-09-30 Merck Sharp & Dohme Optymalizowana ekspresja L1 HPV 52 w drożdżach
DE102004036913A1 (de) * 2004-07-16 2006-02-09 Responsif Gmbh Verwendung von Pentameren zur Herstellung eines Medikaments
CN1796403B (zh) * 2004-12-22 2010-04-28 三峡大学 用于多型人乳头瘤病毒感染防治的多肽和疫苗
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
CN101914139B (zh) * 2010-07-16 2012-11-21 四川大学 人类乳头瘤病毒(hpv)衣壳蛋白l1多肽及其制备与应用
WO2018237115A2 (en) 2017-06-23 2018-12-27 Pathovax Llc CHIMERIC VIRUS-LIKE PARTICLES AND THEIR USES AS SPECIFIC REDIRECTORS OF ANTIGENS OF IMMUNE RESPONSES
WO2020139978A1 (en) 2018-12-27 2020-07-02 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
AU2020218564A1 (en) * 2019-02-08 2021-08-19 Rensselaer Polytechnic Institute A contraceptive vaccine based on the sperm-associated protein Catsper
AU2021364548A1 (en) 2020-10-19 2023-06-08 Verimmune Inc. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0809700T3 (da) * 1994-10-07 2006-09-18 Univ Loyola Chicago Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique
DE19812941A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor

Also Published As

Publication number Publication date
MXPA02003328A (es) 2004-09-10
CN1373771A (zh) 2002-10-09
NO20020615D0 (no) 2002-02-08
TR200200802T2 (tr) 2002-09-23
SE9903534D0 (sv) 1999-09-30
ZA200200886B (en) 2003-03-26
AU7695100A (en) 2001-04-30
HUP0202770A2 (hu) 2002-12-28
BR0014666A (pt) 2002-06-18
DE60025016D1 (de) 2006-01-26
HUP0202770A3 (en) 2004-07-28
HRP20020092A2 (en) 2003-06-30
NO20020615L (no) 2002-05-29
NZ516725A (en) 2003-03-28
JP2003510064A (ja) 2003-03-18
IL148741A0 (en) 2002-09-12
EE200200157A (et) 2003-04-15
RU2002111554A (ru) 2004-03-27
PL355012A1 (en) 2004-03-22
CA2384723A1 (en) 2001-04-05
EP1222200B1 (en) 2005-12-21
SE514982C2 (sv) 2001-05-28
YU22202A (sh) 2005-06-10
ATE313559T1 (de) 2006-01-15
SK4222002A3 (en) 2002-10-08
CZ20021023A3 (cs) 2002-07-17
AU771481B2 (en) 2004-03-25
WO2001023422A1 (en) 2001-04-05
KR20020047195A (ko) 2002-06-21
EP1222200A1 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
HUP0203056A1 (hu) Vakcinakészítmény
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
PT1294893E (pt) Modificacao do antigenio nuclear de hepatite b
HU9904549A (en) Vaccines
BR0316758A (pt) Vacinas baseadas em levedura como imunoterapia
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
HUP0000992A2 (hu) Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
NO976119D0 (no) OMP26-antigen fra Haemophilus influenzae
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
AU2003242535A1 (en) Improved polysaccharide and glycoconjugate vaccines
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
DK1334197T3 (da) Gær-afledt vaccine mod IPNV
ATE335821T1 (de) Verfahren und zusammensetzungen zur diagnose von rochalimaea henselae und rochalimaea quintana infektion
HU9200583D0 (en) Method for producing el peptides of rubeola
EP1667634A4 (en) ANTHRAX VACCINE
CY1108781T1 (el) Εμβολιο ψαριων
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
DK1227840T3 (da) Adjuverede, genetiske vacciner
GB8906796D0 (en) Method of enhancing neutralising antibody activity in human or animal sera or in other body secretions

Legal Events

Date Code Title Description
NUG Patent has lapsed